Health Catalyst (HCAT) Projected to Post Quarterly Earnings on Wednesday

Health Catalyst (NASDAQ:HCAT - Get Free Report) is expected to be posting its Q1 2025 quarterly earnings results after the market closes on Wednesday, May 7th. Analysts expect the company to announce earnings of $0.01 per share and revenue of $79.17 million for the quarter.

Health Catalyst Trading Down 2.6 %

Shares of Health Catalyst stock traded down $0.11 during trading on Monday, hitting $4.08. The company's stock had a trading volume of 111,465 shares, compared to its average volume of 605,258. The stock has a market cap of $286.46 million, a price-to-earnings ratio of -3.02 and a beta of 1.56. Health Catalyst has a 52 week low of $3.56 and a 52 week high of $9.24. The stock has a 50-day moving average price of $4.18 and a two-hundred day moving average price of $6.06. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41.

Insider Buying and Selling

In other Health Catalyst news, COO Daniel Lesueur sold 16,902 shares of the stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $4.52, for a total transaction of $76,397.04. Following the transaction, the chief operating officer now directly owns 216,250 shares in the company, valued at $977,450. This trade represents a 7.25 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Linda Llewelyn sold 6,441 shares of Health Catalyst stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $5.43, for a total transaction of $34,974.63. Following the transaction, the insider now directly owns 85,819 shares in the company, valued at $465,997.17. This trade represents a 6.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 47,588 shares of company stock worth $225,906. Corporate insiders own 2.50% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently commented on HCAT. Piper Sandler decreased their target price on Health Catalyst from $12.00 to $8.00 and set an "overweight" rating for the company in a research report on Tuesday, February 11th. Canaccord Genuity Group reduced their target price on Health Catalyst from $11.00 to $10.00 and set a "buy" rating for the company in a report on Tuesday, January 21st. KeyCorp lowered their price objective on shares of Health Catalyst from $7.00 to $5.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 16th. Wells Fargo & Company dropped their price target on Health Catalyst from $13.00 to $10.00 and set an "overweight" rating on the stock in a research report on Tuesday, January 21st. Finally, Citigroup cut their price objective on shares of Health Catalyst from $7.00 to $6.50 and set a "buy" rating for the company in a report on Friday, April 25th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat, Health Catalyst currently has an average rating of "Moderate Buy" and an average target price of $8.05.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.